PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Trevigen, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Trevigen Launches Anti-8-oxo-dG Monoclonal Antibody Clone 2E2 - When exposed to oxidative radicals, 8-hydroxy-2’-deoxyguanosine (8-oxo-dG) is formed and can serve as a sensitive indicator of physiological and environmental damage to DNA
Trevigen Launches Anti-8-oxo-dG Monoclonal Antibody Clone 2E2

 

NewswireToday - /newswire/ - Arlington, VA, United States, 2008/03/04 - When exposed to oxidative radicals, 8-hydroxy-2’-deoxyguanosine (8-oxo-dG) is formed and can serve as a sensitive indicator of physiological and environmental damage to DNA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

DNA damage caused by oxidative radicals is associated with aging, inflammation, carcinogenesis, Parkinson’s and Alzheimer’s diseases. When exposed to oxidative radicals, 8-hydroxy-2’-deoxyguanosine (8-oxo-dG) is formed and can serve as a sensitive indicator of physiological and environmental damage to DNA. This mouse monoclonal antibody specifically binds to 8-hydroxy-2’-deoxyguanosine within DNA in H2O2-treated cells.

It can be used to detect oxidative damage by ELISA and immunocytochemistry. For optimal outcomes, cells should be grown on a surface that allows for fixation and direct labeling such as sterile chamber slides and coverslips. This antibody is provided as purified immunoglobulin from mouse ascites in 1X PBS containing 0.01% sodium azide.

Sufficient antibody is provided for approximately 50 slides, when a 1:250 dilution is used (Cat# 4354-MC-050). For details, contact Trevigen by phone at 800-873-8443, by email, or visit the website.

About Trevigen
Trevigen (trevigen.com) is a long standing provider of quality kits and reagents for researchers investigating programmed cell death, DNA damage and repair, cell differentiation and angiogenesis. Trevigen recently launched Anti-8-oxo-dG Monoclonal Antibody (Clone 2E2) as part of it DNA Damage product line.

References:
1 Soultanakis RP, Melamede RJ, Bespalov IA, Wallace SS, Beckman KB, Ames BN, Taatjes DJ, Janssen-Heininger YMW. (2000) Flourescence detection of 8-oxoguanine in nuclear and mitochondrial DNA of cultured cells using a recombinant Fab and confocal scanning laser microscopy. Free Rad Biol Med 28:987-998.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Trevigen, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Trevigen Launches Anti-8-oxo-dG Monoclonal Antibody Clone 2E2

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Anti-8-oxo-dG Monoclonal |
Publisher Contact: Belinda De Leon - Trevigen.com 
1-800-TREVIGEN info[.]trevigen.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Trevigen, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Trevigen, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)